04/06/2026
The medical model of mental health services operates on the premise that psychological distress is primarily a biological phenomenon, viewing mental disorders as physical brain diseases caused by chemical imbalances or genetic abnormalities. This framework prioritizes clinical diagnosis and pharmacological interventions, often treating symptoms like anxiety or depression as malfunctions to be corrected with medication. Critics argue that this dominant model has been significantly bolstered by the influence of "Big Pharma," which benefits from a treatment paradigm centered on pills rather than long-term psychotherapy. The industry’s focus on the medical model is intrinsically linked to its immense profitability; for instance, antidepressants alone have generated over $14 billion in global sales annually. To maintain and expand these "multi-billion-dollar global markets," pharmaceutical companies heavily fund research, clinical trials, and even the development of diagnostic manuals like the DSM, where over half of the task force members have reported financial ties to the industry. This symbiotic relationship has led to the "medicalization of emotions," where normal human experiences are reframed as illnesses to broaden the consumer base for profitable psychotropic drugs.